Financial Analysis: ELEKTA AB/ADR (OTCMKTS:EKTAY) versus Castle Biosciences (OTCMKTS:CSTL)

ELEKTA AB/ADR (OTCMKTS:EKTAY) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Analyst Ratings

This is a summary of current ratings for ELEKTA AB/ADR and Castle Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ELEKTA AB/ADR 0 1 0 0 2.00
Castle Biosciences 0 0 5 0 3.00

Castle Biosciences has a consensus price target of $31.80, indicating a potential downside of 0.53%. Given Castle Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than ELEKTA AB/ADR.

Valuation and Earnings

This table compares ELEKTA AB/ADR and Castle Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ELEKTA AB/ADR $1.44 billion 3.14 $132.74 million $0.33 35.79
Castle Biosciences N/A N/A N/A N/A N/A

ELEKTA AB/ADR has higher revenue and earnings than Castle Biosciences.

Profitability

This table compares ELEKTA AB/ADR and Castle Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ELEKTA AB/ADR 7.77% 14.31% 4.55%
Castle Biosciences N/A N/A N/A

Insider and Institutional Ownership

0.0% of ELEKTA AB/ADR shares are owned by institutional investors. Comparatively, 28.5% of Castle Biosciences shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ELEKTA AB/ADR Company Profile

Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Castle Biosciences Company Profile

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.